Nasdaq QINPREZO™ (vosaroxin) is an anti-cancer quinolone derivative (AQD), a class of compounds that has not been used previously for the treatment of cancer. Preclinical data demonstrate that QINPREZO both intercalates DNA and inhibits topoisomerase II, ... and more »
Nasdaq QINPREZO™ (vosaroxin) is an anti-cancer quinolone derivative (AQD), a class of compounds that has not been used previously for the treatment of cancer. Preclinical data demonstrate that QINPREZO both intercalates DNA and inhibits topoisomerase II, ... and more »
Times of India Indian scientists may have found a game-changing discovery that will shorten treatment for tuberculosis to four months from the standard six-month regimen of medication, trials that included an antibiotic prescribed for infections like pneumonia have ...
MedPage Today Meeting Coverage. ASN Extras: Antibiotics Don't Block BK, Sickle Cell Ups CKD Risk. Published: Nov 19, 2014 | Updated: Nov 19, 2014. By Kristina Fiore, Staff Writer, MedPage Today. Reviewed by F. Perry Wilson, MD, MSCE; Assistant Professor, Section of ... and more »
MarketWatch QINPREZO™ (vosaroxin) is an anti-cancer quinolone derivative (AQD), a class of compounds that has not been used previously for the treatment of cancer. Preclinical data demonstrate that QINPREZO both intercalates DNA and inhibits topoisomerase II, ... and more »
CNNMoney QINPREZO™ (vosaroxin) is an anti-cancer quinolone derivative (AQD), a class of compounds that has not been used previously for the treatment of cancer. Preclinical data demonstrate that QINPREZO both intercalates DNA and inhibits topoisomerase II, ... and more »
ConsumerReports.org For example, take it with tetracycline or quinolone antibiotics such as ciprofloxacin (Cipro and generic) and you'll reduce the amount of both the zinc and the antibiotic that your body absorbs. It can also interfere with the absorption of ...
